A importância da idade na síndrome metabólica em pacientes portadoras de ovários policísticos

Breno Garcia Cruz de Holanda Cavalcante Garcia Cruz de Holanda Cavalcante, Larissa Habib Mendonça Gois, José Gilmar Costa Santos, Rosileide Alves da Silva, Júlia Maria Gonçalves Dias

Abstract


This study aims to evaluate the prevalence and individual characteristics of the metabolic syndrome
(MBS) in sergipanas women with polycystic ovary syndrome (PCOS) using age as an association
variable. It is a cross-sectional study involving 50 women aged 25-50 years old with PCOS in accord
with Rotterdam criteria (2003). For the diagnosis of metabolic syndrome, the National Cholesterol Education Program’s Adult Treatment Panel III (NCEP-ATP III) was considered. The prevalence of the
MBS was 56%. As for the individual components of MS, was evident: abdominal circumference > 88
cm in 72%, triglycerides ≥ 150 mg/dL in 32%, HDL-cholesterol <50 mg/dl in 54%, fasting glucose ≥ 110
mg/dl in 26%, systolic blood pressure ≥ 130 mmHg in 52% and diastolic blood pressure ≥ 85 mmHg in
40%. Patients aged equal or over 35 years had a higher percentage of Abdominal Circumference (AC)
> 88 cm (40%), modified triglyceride levels (20%), HDL-cholesterol to levels below 50 mg/dl (34%),
altered levels of fasting glucose (22%), systolic blood pressure (SBP) equal to or above 130 mmHg
(36%) and diastolic blood pressure (DBP) equal to or above 85 mmHg (26%). There was a statistically
significant association (p <0.05) between age and the following variables: AC, triglycerides, fasting
glucose and DBP. There was a significant prevalence of MS in more than half the women studied,
indicating increased chances for developing cardiovascular disease (CVD) and pointing out the need for
tracking cardiovascular risk among women with clinical manifestations of PCOS.

Keywords


Polycystic ovary syndrome, Metabolic syndrome, Cardiovascular diseases.

Full Text:

PDF

References


Gadelha RGN, Soares EMM, Silva TMA, Maranhão TMO,

Azevedo GD. Síndrome dos ovários policísticos e síndrome:

uma associação significativa com implicações clínicas.

PublICa. 2005;1(2):68-77.

Fernandes LG. Síndrome dos ovários policísticos: uma

abordagem epidemiológica [tese]. Salvador (BA): Universidade

Federal da Bahia, Instituto de Saúde Coletiva,

Programa de Pós-Graduação em Saúde Coletiva; 2013.

Legro RS. Diagnostic criteria in polycystic ovary syndrome.

Seminars in reproductive medicine. 2003;21(3):267-75.

Speroff LGR, Kase NG. Anovulation and the Polycystic

Ovary. In: Weinberg R, editor. Clinical Gynecologic Endocrinology

and Infertility. Philadelphia: Lippincott Williams

and Wilkins; 2005. p.465-98.

Ehrmann DA. Polycystic ovary syndrome. N Engl J Med.

;352(12):1223-36.

Cussons AJ, Stuckey BG, Watts GF. Cardiovascular disease

in the polycystic ovary syndrome: new insights and

perspectives. Atherosclerosis. 2006;185(2):227-39.

Fernández-Morales D. Manifestaciones clínicas del síndrome

del ovario poliquístico. Acta Médica Costarricense.

;47(4):180-5.

Bhatia V. Insulin resistance in polycystic ovary disease.

South Med J. 2005;98(9):903-10.

Vrbikova J, Cibula D, Dvorakova K, Stanicka S, Sindelka

G, Hill M, et al. Insulin Sensitivity in women with

polycystic ovary syndrome. J Clin Endocrinol Metab.

;89(6):2942-5.

Trolle B, Lauszus FF. Risk factors for glucose intolerance

in Danish women with polycystic ovary syndrome. Acta

Obstet Gynecol Scand. 2005;84(12):1192-6.

Wild S, Pierpoint T, McKeighe P, Jacobs H. Cardiovascular

disease in women with polycystic ovary syndrome

at long-term follow-up: a retrospective cohort study. Clin

Endocrinol (Oxf). 2000;52(5):595-600.

Legro RS. Polycystic ovary syndrome and cardiovascular

disease: a premature association? Endocr Rev.

;24(3):302-12.

Meyer C, McGrath BP, Teede HJ. Overweight women

with polycystic ovary syndrome have evidence of subclinical

cardiovascular disease. J Clin Endocrinol Metab.

;90(10): 5711-6.

Soares EM, Azevedo GD, Gadelha RG, Lemos TM, Maranhão

TM. Prevalence of the metabolic syndrome and

its components in Brazilian women with polycystic ovary

syndrome. Fertil Steril. 2008;89(3):649-55.

Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS,

Ghazzi MN, et al. Prevalence and predictors of the metabolic

syndrome in women with polycystic ovary syndrome.

J Clin Endocrinol Metab. 2006;91(1):48-53.

Meirelles RMR. Menopausa e síndrome metabólica. Arq

Bras Endocrinol Metab. 2014;58(2):91-6.

Hildrum B, Mykletun A, Hole T, Midthjell K, Dahl AA. Age-

-specific prevalence of the metabolic syndrome defined

by the International Diabetes Federation and the National

Cholesterol Education Program: the Norwegian HUNT 2

study. BMC Pub. Health. 2007;7(220):1-9.

Szostak-Wegierek D, Waskiewicz A. Metabolic disorders

in women at procreative age living in Warsaw. Rocz

Panstw Zakl Hig. 2015;66(3):245-251.

Soares EMM, Azevedo GD, Maranhão TMO. Síndrome

Metabólica em Mulheres Com Síndrome dos Ovários Policísticos:

Prevalência em Cidade da Região Nordeste do

Brasil. Arq Bras Endocrinol Metab. 2007;51(6):1027:1028.

Gogia A, Agarwal PK. Metabolic syndrome. Indian J Med

Sci. 2006;60(2):72-81.

Vural B, Caliskan E, Turkoz E, Kilic T, Demirci A. Evaluation

of metabolic syndrome frequency and premature

carotid atherosclerosis in young women with polycystic

ovary syndrome. Hum Reprod. 2005;20(9):2409-13.

Tehrani FR, Montazeri1 SA, Hosseinpanah F, Cheraghi L,

Erfani1 H, Tohidi M, et al. Trend of Cardio-Metabolic Risk

Factors in Polycystic Ovary Syndrome: A Population-Based

Prospective Cohort Study. PLoS ONE. 2015;10(9):1-

Costa LOBF, Viana AOR, Oliveira M. Prevalência da síndrome

metabólica em portadoras da síndrome dos ovários

policísticos. Rev Bras Ginecol Obstet. 2007;29(1):10–17.

Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus

Workshop Group. Revised 2003 consensus on diagnostic

criteria and longterm health risks related to polycystic

ovary syndrome. Fertil Steril. 2004;81(1):19-25.

National Cholesterol Education Program (NCEP) Expert

Panel on Detection, Evaluation, and Treatment of

High Blood Cholesterol in Adults (Adult Treatment Panel

III). Third Report of the National Cholesterol Education

Program (NCEP) Expert Panel on Detection, Evaluation,

and Treatment of High Blood Cholesterol in Adults

(Adult Treatment Panel III) final report. Circulation.

;106(25):3143-421.

Puder JJ, Varga S, Kraenzlin M, de Geyter C, Keller U,

Müller B. Central fat excess in polycystic ovary syndrome:

relation to low-grade inflammation and insulin resistance.

J Clin Endocrinol Metab. 2005;90(4):6014-21.

Centers for Disease Control and Prevention. The Third

National Health and Nutrition Examination Survey (NHANES

III 1988-94) Reference Manuals and Reports. Bethesda,

Md: National Center for Health Statistics; 1996.

Ilanne-Parrika P, Eriksson JG, Lindstrom J, Hamalainen

H, Keinanen-Kiukaanniemi S, Laakso M, et al. Prevalence

of the Metabolic Syndrome and its Components. Diabetes

Care. 2004;27(9):2135-40.

Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic

syndrome among US adults: findings from the Third

National Health and Nutrition Examination Survey. JAMA.

;287(3):356-9.

Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence

and characteristics of the Metabolic Syndrome in

women with polycystic ovary syndrome. J Clin Endocrinol

Metab. 2005;90(4):1929-35.

Ávila MAP, Bruno RV, Barbosa FC, Andrade FC, Silva

ACO, Nardi AE. Síndrome dos ovários policísticos: implicações

da disfunção metabólica. Rev Col Bras Cir.

;41(2):106-11.

Premoli ACG, Moura MD, Ferriani RA, Sá MFS, Reis

RM. Perfil lipídico em pacientes portadoras da síndrome

dos ovários policísticos. Rev Bras Ginecol Obstetr.

;22(2):89-94.

Sathyapalan T, Atkin SL. Mediators of inflammation in

polycystic ovary syndrome in relation to adiposity. Mediators

inflammation. 2010;2010:1-5.

Costa EC, Soares EMM, Lemos TMAM, Maranhão TMO,

Azevedo GD. Índices de obesidad central y factores de

riesgo cardiovascular em el síndrome de ovarios poliquísticos.

Arq Bras Cardiol. 2010;94(5):615–20.

Kandaraki E, Christakou C, Diamanti-Kandarakis E. Metabolic

syndrome and polycystic ovary syndrome… and

vice versa. Arq Bras Endocrinol Metab. 2009;53(2):227-

Kuba VM, Cavaliere PM, Christóforo AC, Faria Júnior R,

Caetano R, Coeli CM, et al. Resistência insulínica e perfil

metabólico em pacientes com síndrome dos ovários

policísticos de peso normal e sobrepeso/obesidade. Arq

Bras Endocrinol Metab. 2006;50(6):1026–33.

Baldani DP, Skrgatic L, Ougouag Roya. Polycystic ovary

syndrome: important underrecognised cardiometabolic

risk factor in reproductive-age women. Inter J Endocrinol.

;2015:1-17.

Martins WP, Soares GM, Vieira CS, Reis RM, Sá

MFS, Ferriani RA. Resistência à insulina em mulheres

com síndrome dos ovários policísticos modifica fatores

de risco cardiovascular. Rev Bras Ginecol Obstet.

;31(3):111–6.

Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors

of dyslipidemia in women with polycystic ovary

syndrome. Am J Med. 2001;111(8):607-13.

Hudecova M, Holte J, Olovsson M, Larsson A, Berne C,

Sundstrom-Paromaa I. Prevalence of the metabolic syndrome

in women with a previous diagnosis of polycystic

ovary syndrome: long-term follow-up. Fertility and Sterility.

;96(5):1271-4.

Gobato AO, Vasques ACJ, Zambon MP, Barros Filho

AA, Hessel G. Síndrome metabólica e resistência à

insulina em adolescentes obesos. Rev Paul Pediatr.

;32(1):55-62.

Passos VMA, Assis TD, Barreto SM. Hipertensão arterial

no Brasil: estimativa de prevalência a partir de estudos

de base populacional. Epidemiol Serv Saúde.

;15(1):35-45.

Dias-da-Costa JS, Olinto MTA, Patrussi AT. Prevalência

de hipertensão arterial sistêmica e fatores associados:

um estudo de base populacional em mulheres no Sul do

Brasil. Cad Saúde Púb. 2007;23(8):1857-66.

Faramawi MF, Delongchamp R, Said Q, Jadhav S, Abouelenien

S. Metabolic syndrome is associated with visit-to-

-visit systolic blood pressure variability in the US adults.

Hypertens Res. 2014;37(9):875-9.




DOI: http://dx.doi.org/10.22565/ijn.v9i2.241

Refbacks

  • There are currently no refbacks.